PPP2R1A mutations are common in the serous type of endometrial cancer

Molecular Carcinogenesis

Volumn 51, Issue 10, 2012, Pages 826-831

  Nagendra, Deepak C ^a   Burke, James ^b   Maxwell, G Larry ^c   Risinger, John I ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Carcinosarcoma; Endometrial cancer; PPP2R1A; Uterine serous carcinoma

Indexed keywords

ARTICLE; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PPP2R1A GENE; PRIORITY JOURNAL; UNDIFFERENTIATED CARCINOMA; UTERUS CARCINOMA;

CARCINOSARCOMA; CELL LINE, TUMOR; CODON; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN PHOSPHATASE 2; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 84866161747     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20850     Document Type: Article

References (44)

1. American Cancer Society. Cancer facts & figures. Atlanta, GA: The Society; 2010. p. v.
2. Deligdisch L, Holinka CF. Endometrial carcinoma: Two diseases? Cancer Detect Prev 1987; 10: 237-246.
3. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995; 76: 2034-2040.
4. Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: Evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004; 92: 719-725.
5. Ferguson SE, Olshen AB, Viale A, Barakat RR, Boyd J. Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clin Cancer Res 2005; 11: 2252-2257.
6. Maxwell GL, Chandramouli GV, Dainty L, et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005; 11: 4056-4066.
7. Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003; 63: 6-11.
8. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53: 5100-5103.
9. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997; 57: 4736-4738.
10. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935-3940.
11. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
12. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006; 12: 5932-5935.
13. Ignar-Trowbridge D, Risinger JI, Dent GA, et al. Mutations of the Ki-ras oncogene in endometrial carcinoma. Am J Obstet Gynecol 1992; 167: 227-232.
14. Kobayashi K, Sagae S, Nishioka Y, Tokino T, Kudo R. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999; 90: 55-59.
15. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65: 10669-10673.
16. Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26: 7158-7162.
17. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992; 52: 1622-1627.
18. Risinger JI, Dent GA, Ignar-Trowbridge D, et al. p53 Gene mutations in human endometrial carcinoma. Mol Carcinog 1992; 5: 250-253.
19. Okamoto A, Sameshima Y, Yamada Y, et al. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991; 51: 5632-5635.
20. Kohler MF, Berkholz A, Risinger JI, Elbendary A, Boyd J, Berchuck A. Mutational analysis of the estrogen-receptor gene in endometrial carcinoma. Obstet Gynecol 1995; 86: 33-37.
21. Kohler MF, Carney P, Dodge R, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996; 175: 1246-1252.
22. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994; 73: 2380-2385.
23. Lopez-Garcia MA, Palacios J. Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 2010; 27: 274-286.
24. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: A review of selected histological subtypes. Cancer Control 2009; 16: 46-52.
25. Cao QJ, Belbin T, Socci N, et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 321-329.
26. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003; 63: 5697-5702.
27. Byron SA, Gartside MG, Wellens CL, et al. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010; 117: 125-129.
28. Shih Ie M, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 2011; 178: 1442-1447.
29. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011; 223: 567-573.
30. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
31. Shi Y. Serine/threonine phosphatases: Mechanism through structure. Cell 2009; 139: 468-484.
32. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009; 1795: 1-15.
33. Mumby M. PP2A: Unveiling a reluctant tumor suppressor. Cell 2007; 130: 21-24.
34. Sablina AA, Hahn WC. The role of PP2A A subunits in tumor suppression. Cell Adh Migr 2007; 1: 140-141.
35. Mumby M. The 3D structure of protein phosphatase 2A: New insights into a ubiquitous regulator of cell signaling. ACS Chem Biol 2007; 2: 99-103.
36. Cho US, Morrone S, Sablina AA, Arroyo JD, Hahn WC, Xu W. Structural basis of PP2A inhibition by small t antigen. PLoS Biol 2007; 5: e202.
37. Cho US, Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 2007; 445: 53-57.
38. Xu Y, Xing Y, Chen Y, et al. Structure of the protein phosphatase 2A holoenzyme. Cell 2006; 127: 1239-1251.
39. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14: 152-160.
40. Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 2008; 27: 147-158.
41. Calin GA, di Iasio MG, Caprini E, et al. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000; 19: 1191-1195.
42. Dainty LA, Risinger JI, Morrison C, et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol 2007; 105: 563-570.
43. Allard JE, Risinger JI, Morrison C, et al. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol 2007; 107: 52-57.
44. Shih Ie M, Wang TL. Mutation of PPP2R1A: A new clue in unveiling the pathogenesis of uterine serous carcinoma. J Pathol 2011; 224: 1-4.